PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
VE303 is a potential first-in-class Live Biotherapeutic Product for the prevention of rCDI, which consists of a defined consortium of eight bacterial strains. Clinical results from Vedanta's successful Phase 2 CONSORTIUM study, published in the Journal of the American Medical Association (JAMA), demonstrated that the higher dose of VE303 studied was well tolerated and reduced the odds of CDI recurrence by more than 80% compared with placebo.
The new publication which is entitled 'Multi-omic Profiling a Defined Bacterial Consortium for Treatment of Recurrent Clostridioides difficile Infection,' reports additional results from CONSORTIUM. Profiling of microbiome composition, fecal metabolites, and host immune function indicated that VE303 works through multiple mechanisms to prevent rCDI by restoring a healthy gut microbial community, decreasing inflammation, and increasing levels of protective metabolites. In addition, the work identified predictors of high or low VE303 colonization and clinical response.
Taken together, these results demonstrate that VE303 works through multiple mechanisms to reduce CDI recurrence. Results from the CONSORTIUM study informed the design and dose selection for the global, pivotal Phase 3 study, RESTORATiVE303, that is currently underway to confirm the efficacy and safety profile of VE303 in the prevention of rCDI. Topline data for this study are expected in 2026.
The full text of the announcement from Vedanta is as follows:
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms
Analyses identified predictors of VE303 colonization and protection from CDI recurrence
Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026
CAMBRIDGE, Mass., January 23, 2025 -- Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from the Phase 2 CONSORTIUM study for its lead candidate, VE303, which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). The new analyses were published this month in Nature Medicine and can be viewed online.
VE303 is a potential first-in-class Live Biotherapeutic Product for the prevention of rCDI, which consists of a defined consortium of eight bacterial strains. Clinical results from Vedanta's successful Phase 2 CONSORTIUM study, published in the Journal of the American Medical Association (JAMA), demonstrated that the higher dose of VE303 studied was well tolerated and reduced the odds of CDI recurrence by more than 80% compared with placebo. VE303 organisms rapidly and robustly colonize the gut in a dose-dependent manner. Colonization predicted greater recurrence-free probability, establishing a direct connection between exposure and clinical response.
The publication which is entitled 'Multi-omic Profiling a Defined Bacterial Consortium for Treatment of Recurrent Clostridioides difficile Infection,' reports additional results from CONSORTIUM. Profiling of microbiome composition, fecal metabolites, and host immune function indicated that VE303 works through multiple mechanisms to prevent rCDI by restoring a healthy gut microbial community, decreasing inflammation, and increasing levels of protective metabolites. In addition, the work identified predictors of high or low VE303 colonization and clinical response.
'This clinical research offers new insights into the mechanisms of action of VE303, providing a rationale for the drug's protective effects in rCDI,' said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. 'Due to VE303's precisely known, defined composition, we can study its mechanisms of action and PK-PD relationships in a rigorous way, taking a step towards understanding why some patients respond better than others to a microbiome restoration intervention. We believe this line of work helps fill a knowledge gap in the field, since characterization of the mechanisms of action of first-generation fecal microbiota products has been very limited.'
Highlights of the publication include:
Abundance of specific VE303 strains, and of VE303 strains overall, was predictive of remaining recurrence-free.
The strains that colonized well differed across individuals, suggesting that efficacy is derived from strains working together as a consortium.
VE303 colonization and clinical benefit correlated with increased levels of short-chain fatty acids and key secondary bile acids, both of which have beneficial effects in conferring resistance to CDI.
Faster recovery of a more diverse microbiome, which was seen in the high dose recipients of VE303, was associated with non-recurrence.
The elimination rate of the antibiotic used for the CDI episode was a predictor of VE303 colonization. Given that clearance of residual antibiotic from stool varies significantly among individuals and can take a week or longer, treating with VE303 for 14 consecutive days following completion of standard-of-care antibiotics enabled VE303 strains to be inoculated when the intestinal environment was most permissive to colonization.
VE303 use led to lower levels of pro-inflammatory and potentially pathogenic Gram-negative species, including Klebsiella and Citrobacter, that are linked to CDI recurrence and AMR bacterial infections.
Taken together, these results demonstrate that VE303 works through multiple mechanisms to reduce CDI recurrence. Results from the CONSORTIUM study informed the design and dose selection for the global, pivotal Phase 3 study, RESTORATiVE303, that is currently underway to confirm the efficacy and safety profile of VE303 in the prevention of rCDI. Topline data for this study are expected in 2026.
This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50120C00177.
About VE303
VE303 is a potential first-in-class Live Biotherapeutic Product for the prevention of recurrent Clostridioides difficile infection (rCDI). VE303 is an orally administered, defined bacterial consortium therapeutic candidate which consists of eight strains that were rationally selected using Vedanta's product engine. VE303 is produced from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypass the need to rely on direct sourcing of donor fecal material of inconsistent composition. Vedanta published positive results in JAMA in April 2023 from the Phase 2 CONSORTIUM trial, in which VE303 met its primary endpoint of preventing C. difficile infection recurrence at eight weeks. Vedanta is currently enrolling patients into a Phase 3 RESTORATiVE303 registrational study of VE303 for the prevention of recurrent C. difficile infection. Vedanta Biosciences received a $5.4 million research grant from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) in 2017 and a contract of up to $81.9 million from Biomedical Advanced Research and Development Authority (BARDA) in 2020 to support clinical studies of VE303. VE303 was granted Orphan Drug Designation in 2017 by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent CDI.
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases. The company's lead assets are potential first-in-class oral therapies – VE303, in a Phase 3 registrational trial for prevention of recurrent C. difficile infection, and VE202, in a Phase 2 trial for treatment of ulcerative colitis. Vedanta's pipeline has been built using the company's industry-leading product engine for the development of therapies based on defined consortia of bacteria grown from pure clonal cell banks. The product engine, supported by broad foundational intellectual property, includes one of the largest libraries of bacteria isolated from the human microbiome, vast clinical datasets, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing capabilities at commercial launch scale.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to Vedanta's development plans for its pipeline of therapeutics of defined bacterial consortia as oral therapies for gastrointestinal diseases, including VE303, the timing of topline results for ongoing clinical trials, potential benefits to patients, and Vedanta's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Public Relations
[email protected]
[email protected] /EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
[email protected] Media
Justin Chen
+1 609 578 7230
[email protected]
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: PureTech Health plc
Copyright Business Wire 2025.
PUB: 01/27/2025 02:00 AM/DISC: 01/27/2025 02:00 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
Moody's Wildfire Risk Model Successfully Completes California Department of Insurance Review Process
NEW YORK--(BUSINESS WIRE)--Moody's Corporation (NYSE:MCO) announced today that the Moody's RMS U.S. Wildfire Model v2.0 has successfully completed the review process established by the California Department of Insurance (CDI). This critical milestone will enable insurers to use the forward-looking catastrophe model in their residential rate filings, supporting California's Sustainable Insurance Strategy aimed at stabilizing the state's property insurance market. The Moody's wildfire risk model will allow insurers to leverage the model's advanced, science-driven analytics to assess and price wildfire risk. This enhanced risk assessment is designed to support a more resilient and accessible insurance market – particularly in wildfire-prone areas. 'At Moody's, we are committed to providing markets with transparent, scientifically rigorous tools to decode today's interconnected risks,' said Michael Steel, Head of Insurance Solutions at Moody's. 'Today's milestone marks a significant step forward in addressing the complexities of wildfire risk and promoting greater resilience for insurers, regulators, and homeowners alike.' The Moody's RMS U.S. Wildfire Model v2.0 represents a major advance in capturing the complexities of wildfire behavior, including extreme urban conflagration events. A key feature of the model is its ability to directly account for property-level and community-wide mitigation efforts. By incorporating property-specific data aligned with California regulations, the model will empower insurers to recognize and reward homeowners for risk-reduction efforts, creating tangible incentives that strengthen resilience. Moody's RMS U.S. Wildfire Model v2.0 was reviewed under the CDI's rigorous Pre-Application Required Information Determination procedure, which includes extensive examination of its hazard, vulnerability, and actuarial components. Already in use by leading global insurers, reinsurers, and financial institutions, the model is available on the Moody's RMS Intelligence Risk Platform™ along with Risk Modeler™ and ExposureIQ™ to support a full range of wildfire risk management activities. About Moody's Corporation In a world shaped by increasingly interconnected risks, Moody's (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of approximately 16,000 across more than 40 countries, Moody's gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at 'Safe Harbor' statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this document are forward-looking statements and are based on future expectations, plans and prospects for Moody's business and operations that involve a number of risks and uncertainties. Such statements involve estimates, projections, goals, forecasts, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements. Stockholders and investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements and other information in this document are made as of the date hereof, and Moody's undertakes no obligation (nor does it intend) to publicly supplement, update or revise such statements on a going-forward basis, whether as a result of subsequent developments, changed expectations or otherwise, except as required by applicable law or regulation. Factors, risks and uncertainties as well as other risks and uncertainties that could cause Moody's actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements are described in greater detail under 'Risk Factors' in Part I, Item 1A of Moody's annual report on Form 10-K for the year ended December 31, 2024, and in other filings made by the Company from time to time with the SEC or in materials incorporated herein or therein. Stockholders and investors are cautioned that the occurrence of any of these factors, risks and uncertainties may cause the Company's actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements, which could have a material and adverse effect on the Company's business, results of operations and financial condition.
Gizmodo
8 hours ago
- Gizmodo
Diet Swap Study Reveals How Ultra-Processed Foods Can Derail Weight Loss
In case you needed more incentive to cut down on ultra-processed foods, a new diet swap study out today reveals that people experienced greater weight loss while eating minimally processed foods than they did when they ate a nutritionally similar, ultra-processed diet. In a six-month trial led by scientists at University College London, study participants were assigned one of the two diet regimes to follow for eight weeks, and then took a four week break before swapping to the other diet for another eight weeks. Participants lost more weight while eating the minimally processed diet than the ultra-processed one; they also shed more unhealthy fat. The findings, published Monday in Nature Medicine, suggest that, among other things, ultra-processed diets are especially good at stoking people's food cravings, the researchers said. Ultra-Processed Foods Have Disturbing Health Effects, Large Review Finds Although there is some debate over what constitutes an ultra-processed food, there are generally considered products or ingredients that have gone through high levels of industrialized processing, like breakfast sausages, candy, or sodas. There is a growing mountain of evidence that suggests a diet rich in ultra-processed foods is less healthy overall than a diet made up of mostly whole foods, and that ultra-processed foods may raise the risk of certain diseases. Most of this research, however, only shows a correlation between ultra-processed diets and poorer health outcomes, and not a direct cause-and-effect link. Clinical trials can provide stronger evidence, but they're notoriously difficult to do in the world of nutrition science for many reasons, particularly funding, the researchers said. A New Diet Study Confirms Your Worst Suspicions About Ultra-Processed Foods The results highlight the importance of following government dietary guidelines, Dicken said. But the study also indicates that people who want to lose weight may see the most benefit from sticking to minimally processed foods. As to why the ultra-processed foods are worse for dieting, the researchers have their educated guesses. Ultra-processed foods tend to have more appealing textures and artificially boosted flavors, which often means they are softer or easier to eat, and tastier. Their appearance and packaging might also make them more visually appealing to potential customers. Interestingly, the volunteers in this study reported that both diets were equally satisfying to eat on average, but they also reported having better control over their cravings while on the minimally processed diet. Dicken noted that the researchers weren't able to directly test these potential explanations in this trial, though, so more research is needed to know for sure. The team has already launched their next study, which is testing out a behavioral support program to reduce people's intake of ultra-processed foods. But Dicken cautioned that it will take widespread societal shifts, not individual scolding, to change our collective diets for the better.
Yahoo
8 hours ago
- Yahoo
Want to lose weight? New study sheds light on how processed foods affect our health
People who cook minimally processed meals at home lose more weight than if they eat ready-made, ultra-processed meals – even if these foods are healthy, a new UK study has found. Food experts have long pointed to ultra-processed foods as a key driver of the obesity crisis, which affects about one in eight people worldwide. These foods are often high in saturated fats, sugar, and salt, for example crisps, frozen dinners, and processed meats. But they also include staples like wholemeal sliced bread and baked beans, meaning ultra-processed foods are not always unhealthy. That's prompted much debate over whether it's the ingredients or the processing itself that really matters when it comes to our health. The latest study, published in the journal Nature Medicine, indicates that minimally processed diets are better for weight loss – but that diets rich in ultra-processed foods can still be healthy as long as they meet nutritional guidelines. Related Butter linked to higher death risk while plant-based oils may boost health 'Completely cutting [ultra-processed foods] out of our diets isn't realistic for most of us,' Tracy Parker, nutrition lead at the British Heart Foundation, said in a statement. 'But including more minimally processed foods – like fresh or home cooked meals – alongside a balanced diet could offer added benefits too,' added Parker, who was not involved with the study. What the study found The findings are based on a small clinical trial involving 55 adults in England. Before the study, the participants tended to have poor nutrition diets made up largely of ultra-processed foods, and on average, they had a body mass index (BMI) of about 33, which is considered obese. The trial split adults into two groups. One group started on a diet of minimally processed foods like homemade spaghetti bolognese or overnight oats, while the other ate only ultra-processed foods like ready-made lasagnas or breakfast cereals. After a monthlong break, the two groups swapped, eating meals from the other diet for another eight weeks. Notably, both of these diets met the United Kingdom's guidelines for a healthy, balanced diet, which takes into account levels of saturated fat, protein, carbohydrates, salt, and fibre, as well as fruit and vegetable intake. The only difference was how processed these meals were. Related Diets rich in ultra-processed foods linked to higher risk of early death, new study warns By the end of the study, both groups lost weight – but adults lost twice as much weight when they were on the minimally-processed diets. They lost about 2 per cent of their weight on this diet, compared with about 1 per cent on the ultra-processed diet. 'Though a 2 per cent reduction may not seem very big, that is only over eight weeks and without people trying to actively reduce their intake,' said Samuel Dicken, a researcher who helped run the trial at University College London. 'Over time this would start to become a big difference,' he added. Over the course of a year, men on the minimally processed diet would be expected to lose 13 per cent of their weight, compared with 4 per cent on the ultra-processed diet, the researchers said. For women, the findings translate to a 9 per cent weight reduction on the minimally processed diet and a 4 per cent reduction on the ultra-processed diet. Dietary differences People tended to lose more weight on the minimally processed diet because of reductions in their fat mass and body water, which the researchers said suggested they had a healthier body composition overall. They also reported fewer food cravings on the minimally processed diet. There were no big differences between the two diets when it came to other health outcomes, such as blood pressure, heart rate, and blood markers that track liver function, blood sugar, cholesterol, and inflammation. The fact that people still lost weight while on ultra-processed diets indicates that these foods aren't all bad, independent experts said. 'The most interesting result of the study is that participants on both arms lost weight – which contradicts claims that ultra-processed foods result in weight gain,' Gunter Kuhnle, a professor of nutrition and food science at the University of Reading, said in a statement. The findings 'suggest that a diet meeting current dietary recommendations is not detrimental to weight maintenance, whether it is ultra-processed or not,' added Kuhnle, who was not involved with the study. Related Ultra-processed foods account for nearly half of calories eaten by UK toddlers, study finds The study also has some limitations, namely the fact that it included only 55 people who tried both diets. Independent researchers warned that it takes time for the body to get used to new eating habits, so longer studies with more people would be needed to understand exactly how ultra-processed foods affect our health. Even so, researchers said the results are in line with other studies showing that access to nutritious food is critical to our health and wellbeing. Dr Chris van Tulleken, one of the study's authors and a researcher studying how corporations affect human health at University College London, pointed to the 'wide availability of cheap, unhealthy food' as a key driver of obesity and poor health worldwide. He called for policy action to make unhealthy options less appealing, for example through warning labels, marketing restrictions, and taxes. The study, he said, 'underlines the need to shift the policy focus away from individual responsibility and on to the environmental drivers of obesity'.
